- Home
- KPRX
as 12-18-2024 4:00pm EST
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | ENCINITAS |
| Market Cap: | 10.0M | IPO Year: | N/A |
| Target Price: | $10.00 | AVG Volume (30 days): | 34.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.69 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.00 - $8.98 | Next Earning Date: | 11-08-2024 |
| Revenue: | $16,020,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -87.89% |
Latest Kiora Pharmaceuticals Inc. News
KPRX Breaking Stock News: Dive into KPRX Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative
Newsfile
a month ago
Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies
TipRanks
2 months ago
Kiora Pharmaceuticals Gains Approval for Phase 2 Trial
Newsfile
2 months ago
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa
Newsfile
3 months ago
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences
Argus Research
3 months ago
Daily – Vickers Top Insider Picks for 09/13/2024
MT Newswires
4 months ago
Kiora Pharmaceuticals Shares Rise After Q2 Loss Narrows
Newsfile
4 months ago
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies
Compare KPRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KPRX Kiora Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.